Endomag strengthens team with appointment of Chief Medical Officer

Cancer healthcare company Endomag has appointed Dr Elizabeth Holmes, Fellow of the Faculty of Public Health, as Chief Medical Officer to further strengthen its management team and support its growing device portfolio.

Dr Holmes joins Endomag from Taiho Pharma where she served as European Medical Director. She brings 26 years' experience in the healthcare sector spanning Public Health, vaccinology and solid tumour oncology through research, clinical development and medical director roles. Dr Holmes has held previous executive roles with Daiichi Sankyo and Biogen-Idec in oncology therapeutics and with Sanofi Pasteur where she helped to launch a ground-breaking vaccine for the prevention of cervical cancer.

Dr Eric Mayes, CEO at Endomag, said: "Dr Holmes is joining us at a time that we are driving growth through portfolio innovations and international expansion. Critical to this growth are increased customer focus and clinical engagement, and Dr Holmes' background as a leader in Public Health and the pharmaceutical industry aligns with our focus on innovative devices that address the needs of clinicians and patients. The fact that she maintains her certifications to practice medicine in the UK and is licensed in Germany highlights both her passion and her sensitivity to the challenges of the current healthcare environment."

As Endomag's CMO, Dr Holmes will support the development of its current products to address new cancer indications by increasing clinician engagement. She will also utilise her background in oncology therapeutics to develop the therapeutic potential of the company's device portfolio.

Dr Holmes said: "Opportunities to work with dynamic companies such as Endomag do not come around very often and I am so pleased to be part of the team. Endomag's advanced magnetic device platform has a vital place in the cancer healthcare market, and I really believe its products will improve the care that cancer patients receive and clinicians offer. I'm looking forward to spreading this message to the industry and wider public, and contributing significantly to its development. This is an exciting time for the company and I am thrilled to be a part of it."

Dr Holmes is a Fellow of the Faculty of Public Health of the Royal College of Physicians and obtained her medical degree from the University of Heidelberg, her MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, and her BA/MA in Natural Sciences from the University of Cambridge.

ENDS

Image:
Dr Elizabeth Holmes, Endomag's newly appointed CMO

Notes to Editors:

Endomag is dedicated to improving the global standard cancer care for everyone, everywhere, by developing a new, effective clinical platform that uses safe magnetic fields to power diagnostic and therapeutic devices.

Endomag's first approved products are the Sentimag® and Sienna+®, CE-approved for marketing and sales in Europe, and TGA-approved for Australasia. Sienna+® is a magnetic tracer injected into the body and the Sentimag® is used to track its presence, locating lymph nodes as part of a sentinel lymph node biopsy (SLNB) procedure.

By avoiding the need for traditional radioactive isotopes in sentinel lymph node biopsy, Sentimag® and Sienna+® improve workflow and lower costs, enhance patient comfort and quality of life, and provide a better standard of care available to everyone, everywhere.

Visit www.endomag.com


PR media contacts: Nicola Collenette / Charlie Hopkinson
E: [email protected] / [email protected]
T: +44 (0)1223 841699 / +44(0)7711 372820

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.